The PLoS ONE science journal published an interesting study performed by the Brain and Aging Research Program at the University of New South Wales in Sydney, Australia. The study sampled apolipoprotein levels in blood samples from over 600 older adults participating in the ongoing Sydney Memory and Aging Study. Apolipoproteins are proteins that transport cholesterol [...]

A topic that received a lot of attention at the University of California San Diego School of Medicine update on Alzheimer’s research was the use of Eli Lilly’s Amyvid for detection of amyloid beta deposits in the brain, one of the physical signatures of Alzheimer’s Disease. Dr. Gil Rabinovici, MD, a physician and researcher at [...]

What is Mild Cognitive Impairment? Mild Cognitive Impairment, or MCI, is an intermediate stage condition between normal cognitive functioning and Alzheimer’s disease or other types of dementia: Signs of MCI include a “change in cognition” — this typically means memory problems, but it can also include planning and reasoning skills that could negatively affect higher [...]

A timely article in the medical journal Neurology speaks to some impending issues that millions of patients and physicians will be facing over the next decade, namely the possible early diagnosis of Alzheimer’s Disease in the pre-clinical phase, before functional cognitive impairment is present. New computerized cognitive testing tools and experimental biomarker tests are bringing [...]

A recent article in Journal of Alzheimer’s Disease discussed several inconvenient facts on the state of Alzheimer’s research, namely that the almost singular focus on amyloid beta protein as the cause of Alzheimer’s Disease (AD) has produced a remarkable string of failures in drug trials that target removal of amyloid beta in the brain. Authored [...]